Interleukin‐6: A Cytokine for Gerontolgists

Interleukin‐6 (IL‐6) is a multifunctional cytokine that presumably plays its major role as a mediator of several of the acute phase inflammatory responses. These include inflammatory cell and lymphocyte activation and hepatocellular stimulation of acute phase protein synthesis. IL‐6 expression is normally low, and serum levels are usually non‐detectable in the absence of inflammation. However, with advancing age, serum levels become detectable, and it is proposed that this reflects an age‐associated loss in the normal regulation of gene expression for this molecule. The cause of this is most likely multi‐factorial, but there is evidence that it relates to an age‐associated loss of T cell immunoregulatory functions as well as menopausal loss of estrogen. In any event, the “inappropriate” presence of IL‐6 results in many changes typical of chronic inflammation. There is also speculation that IL‐6 may contribute to the pathogenesis of several diseases of late‐life including lymphoma, osteoporosis, and Alzheimer's disease. In this review the biology of this important cytokine is presented and its relevance to gerontology is highlighted.

[1]  W. Ershler,et al.  In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. , 1992, Cancer research.

[2]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[3]  K S Kosik,et al.  Alzheimer's disease: a cell biological perspective. , 1992, Science.

[4]  G. Roodman Perspectives: Interleukin‐6: An osteotropic factor? , 1992 .

[5]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[6]  G. Passeri,et al.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.

[7]  J. Bauer,et al.  Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[8]  M. Kluger,et al.  Fever, tumor necrosis factor, and interleukin-6 in young, mature, and aged Fischer 344 rats. , 1992, The American journal of physiology.

[9]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[10]  J. Bauer,et al.  IL-6-mediated events in Alzheimer's disease pathology. , 1991, Immunology today.

[11]  H. Müller-Hermelink,et al.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. , 1991, The American journal of pathology.

[12]  B. Klein,et al.  Letter to the editor: The bone‐resorbing activity of interleukin‐6 , 1991 .

[13]  M. Gowen Reply: The bone‐resorbing activity of interleukin‐6 , 1991 .

[14]  R. Effros,et al.  Influence of age and caloric restriction on macrophage IL-6 and TNF production. , 1991, Lymphokine and cytokine research.

[15]  W. Fiers,et al.  Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? , 1991, Immunology today.

[16]  A. Kuramoto,et al.  Interleukin-6 produced by renal-cell carcinoma cells and progression of multiple myeloma. , 1991, The New England journal of medicine.

[17]  C. Masters,et al.  In‐vitro matured human macrophages express Alzheimer's βA4‐amyloid precursor protein indicating synthesis in microglial cells , 1991, FEBS letters.

[18]  K. Beyreuther,et al.  Alpha 2‐macroglobulin synthesis in interleukin‐6‐stimulated human neuronal (SH‐SY5Y neuroblastoma) cells Potential significance for the processing of Alzheimer β‐amyloid precursor protein , 1991 .

[19]  S. Akira,et al.  Age-associated increase in interleukin 6 in MRL/lpr mice. , 1991, International immunology.

[20]  S. Ralston,et al.  Interleukin‐6 does not stimulate bone resorption in neonatal mouse calvariae , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[22]  T. Hirano,et al.  IL-6 is produced by osteoblasts and induces bone resorption. , 1990, Journal of immunology.

[23]  M. Jourdan,et al.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.

[24]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[25]  T. Suda,et al.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.

[26]  H. Potter,et al.  α 1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α 1-antichymotrypsin , 1990, Neurobiology of Aging.

[27]  M. Jourdan,et al.  Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. , 1990, Arthritis and rheumatism.

[28]  S. Rosenberg,et al.  Antitumor activity of recombinant interleukin 6 in mice , 1990, The Journal of experimental medicine.

[29]  J. Snick,et al.  Interleukin-6: an overview. , 1990, Annual review of immunology.

[30]  J. Radl,et al.  Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. , 1990, Immunology today.

[31]  T. Hirano,et al.  Interleukin 6 (IL-6) , 1990, Biotherapy.

[32]  G. Ciliberto,et al.  Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6. , 1989, The EMBO journal.

[33]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[34]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[35]  X. H. Wang,et al.  A possible autocrine role for interleukin-6 in two lymphoma cell lines. , 1989, Blood.

[36]  Masahiro Yamamoto,et al.  Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas , 1989, FEBS letters.

[37]  M. Jourdan,et al.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. , 1989, Blood.

[38]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.

[39]  S. Akira,et al.  Genomic structure of the murine IL-6 gene. High degree conservation of potential regulatory sequences between mouse and human. , 1988, Journal of immunology.

[40]  R. Moritz,et al.  Murine hybridoma/plasmacytoma growth factor. Complete amino-acid sequence and relation to human interleukin-6. , 1988, European journal of biochemistry.

[41]  J. Vilček,et al.  Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Taniguchi,et al.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.

[43]  H. Asaoku,et al.  Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. , 1988, Blood.

[44]  J. Vilček,et al.  Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. , 1988, The Journal of biological chemistry.

[45]  S. Clark,et al.  Multiple actions of interleukin 6 within a cytokine network. , 1988, Immunology today.

[46]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[47]  P. Sehgal,et al.  Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). , 1988, Science.

[48]  J. Ihle,et al.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Clark,et al.  B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Hirano,et al.  Structure and expression of human B cell stimulatory factor‐2 (BSF‐2/IL‐6) gene. , 1987, The EMBO journal.

[51]  J H Korn,et al.  Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines. , 1986, The EMBO journal.

[52]  F. Ruddle,et al.  Human chromosome 7 carries the beta 2 interferon gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Frith,et al.  Contributions of recent research to the classification of spontaneous lymphoid cell neoplasms in mice. , 1986, Critical reviews in toxicology.

[54]  C. Taylor,et al.  Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. , 1983, The American journal of pathology.

[55]  C. Frith,et al.  Spontaneous lesions in virgin and retired breeder BALB/c and C57BL/6 mice. , 1983, Laboratory animal science.

[56]  C. Frith,et al.  Morphologic classification and correlation of incidence of hyperplastic and neoplastic hematopoietic lesions in mice with age. , 1981, Journal of gerontology.

[57]  J. Radl,et al.  Immunoglobulin patterns in humans over 95 years of age. , 1975, Clinical and experimental immunology.